Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA ® (tigilanol tiglate) removes 75% of tumours

17 June 2020 The study of 123 client-owned dogs demonstrated that in those with Mast Cell Tumours (MCTs), a single intratumoural injection of STELFONTA ® removed 75% of MCTs at day 28, significantly higher compared to untreated controls (p<0.001). Further, the trial showed no recurrence in 93% of STELFONTA ® -treated dogs at day 84. Read the full media release

The release as fetched from its publisher. qbiotics.com ↗